Literature DB >> 10840038

14-3-3zeta is an effector of tau protein phosphorylation.

M Hashiguchi1, K Sobue, H K Paudel.   

Abstract

Neurofibrillary tangles associated with Alzheimer's disease are composed mainly of paired helical filaments that are formed by the aggregation of abnormally phosphorylated microtubule-associated protein tau. 14-3-3, a highly conserved protein family that exists as seven isoforms and regulates diverse cellular processes is present in neurofibrillary tangles (Layfield, R., Fergusson, J., Aitken, A., Lowe, J., Landon, M., Mayer, R. J. (1996) Neurosci. Lett. 209, 57-60). The role of 14-3-3 in Alzheimer's disease pathogenesis is not known. In this study, we found that the 14-3-3zeta isoform is associated with tau in brain extract and profoundly stimulates cAMP-dependent protein kinase catalyzed in vitro phosphorylation on Ser(262)/Ser(356) located within the microtubule-binding region of tau. 14-3-3zeta binds to both phosphorylated and nonphosphorylated tau, and the binding site is located within the microtubule-binding region of tau. From brain extract, 14-3-3zeta co-purifies with microtubules, and tubulin blocks 14-3-3zeta-tau binding. Among four 14-3-3 isoforms tested, beta and zeta but not gamma and epsilon associate with tau. Our data suggest that 14-3-3zeta is a tau protein effector and may be involved in the abnormal tau phosphorylation occurring during Alzheimer's disease ontogeny.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840038     DOI: 10.1074/jbc.M003738200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  63 in total

1.  Identification of cofilin and LIM-domain-containing protein kinase 1 as novel interaction partners of 14-3-3 zeta.

Authors:  Jörg Birkenfeld; Heinrich Betz; Dagmar Roth
Journal:  Biochem J       Date:  2003-01-01       Impact factor: 3.857

2.  14-3-3 proteins in neurological disorders.

Authors:  Molly Foote; Yi Zhou
Journal:  Int J Biochem Mol Biol       Date:  2012-05-18

Review 3.  Actin dynamics and cofilin-actin rods in alzheimer disease.

Authors:  James R Bamburg; Barbara W Bernstein
Journal:  Cytoskeleton (Hoboken)       Date:  2016-03-01

4.  PAK5 kinase is an inhibitor of MARK/Par-1, which leads to stable microtubules and dynamic actin.

Authors:  Dorthe Matenia; Bettina Griesshaber; Xiao-yu Li; Anja Thiessen; Cindy Johne; Jian Jiao; Eckhard Mandelkow; Eva-Maria Mandelkow
Journal:  Mol Biol Cell       Date:  2005-07-12       Impact factor: 4.138

5.  A pilot proteomic study of amyloid precursor interactors in Alzheimer's disease.

Authors:  Barbara A Cottrell; Veronica Galvan; Surita Banwait; Olivia Gorostiza; Christian R Lombardo; Tristan Williams; Birgit Schilling; Alyson Peel; Bradford Gibson; Edward H Koo; Christopher D Link; Dale E Bredesen
Journal:  Ann Neurol       Date:  2005-08       Impact factor: 10.422

6.  Identification of AGE-modified proteins in SH-SY5Y and OLN-93 cells.

Authors:  André K Langer; H Fai Poon; Gerald Münch; Bert C Lynn; Thomas Arendt; D Allan Butterfield
Journal:  Neurotox Res       Date:  2006-06       Impact factor: 3.911

Review 7.  14-3-3/Tau Interaction and Tau Amyloidogenesis.

Authors:  Yuwen Chen; Xingyu Chen; Zhiyang Yao; Yuqi Shi; Junwen Xiong; Jingjing Zhou; Zhengding Su; Yongqi Huang
Journal:  J Mol Neurosci       Date:  2019-05-06       Impact factor: 3.444

8.  14-3-3 proteins interact with the beta-thymosin repeat protein Csp24.

Authors:  Terry Crow; Juan-Juan Xue-Bian; Joseph T Neary
Journal:  Neurosci Lett       Date:  2007-08-01       Impact factor: 3.046

Review 9.  Redox proteomics and amyloid β-peptide: insights into Alzheimer disease.

Authors:  D Allan Butterfield; Debra Boyd-Kimball
Journal:  J Neurochem       Date:  2018-11-27       Impact factor: 5.372

10.  Synaptic proteins linked to HIV-1 infection and immunoproteasome induction: proteomic analysis of human synaptosomes.

Authors:  Benjamin B Gelman; Trung P Nguyen
Journal:  J Neuroimmune Pharmacol       Date:  2009-08-20       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.